Changrui Biotech held the groundbreaking ceremony and the awarding ceremony of the three bases

Category:

Release time:2023-02-02

On July 18, 2022, the groundbreaking ceremony of the first phase of CDMO laboratory construction and the unveiling ceremony of the three major bases of Changrui Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as "Changrui Biotechnology") were held in Chengdu Tianfu International Biocity.

Changrui Biotech is the first local biopharmaceutical R&D and industrialization CDMO enterprise in Sichuan, with 6 major technology platforms, more than ten exclusive national products under research and a complete quality management system in line with Sino-US double report.

Deng Fei, General Manager of Changrui Biotechnology, Director Li of the Biocity Management Committee, Zeng Secretary-General of Chengdu High-tech Medical Association, and Professor Zhao Jian of the School of Life Sciences of Sichuan University jointly launched the groundbreaking ceremony of the first phase of the CDMO laboratory of Changrui Biotechnology.

As a model of school-enterprise cooperation and industry-university-research cooperation, the three bases of Sichuan University and Chengdu High-tech Medical Association were successfully completed on the same day, namely "Collaborative Innovation Base for Medical-Engineering Integration", "Transformation Base for Scientific and Technological Innovation Achievements in Biomacromolecular Drugs", and "Biomedical Product R&D and Technical Service Practice Teaching Base" of the awarding ceremony.

Deng Fei, General Manager of Changrui Biotechnology,

welcomed everyone to witness this milestone moment of Changrui Biotechnology, from the pain of entrepreneurship to the sweetness of progress to now ushering in greater development opportunities, the success of the enterprise is inseparable from the intimate warmth and strong support of the bio-city family. Changrui Biotech strives to be among the pioneers of China's biopharmaceutical CDMO industry in 3~5 years, become a member of the outstanding family in Chengdu Tianfu International Biocity, and with the completion of the second and third phase laboratories, achieve the goal of building a first-class domestic and leading macromolecular biopharmaceutical CDMO one-stop service platform in line with Sino-US double report, and contribute acceleration to China's biomedical innovation vision.

The guests who participated in this event spoke highly of the development of Changrui Biotechnology and the persistence of General Manager Deng Fei in the entrepreneurial process.

Dr. Li Jinling, General Manager of Chengdu Biotech Co., Ltd., gave more expectations and blessings for the joint development of the two enterprises in the future through the review of the efficient cooperation with Changrui Biotechnology.

Zeng Bin, Secretary-General of Chengdu High-tech Medical Association, mentioned the strategic planning of the High-tech Medical Association, believing that Changrui Biotech's perfect technical capabilities and the goal of serving the transformation of biological drug achievements are highly compatible with the medical association, and looks forward to the two sides working together to create a new model of pharmaceutical ecosystem!

Professor Zhao Jian from the School of Life Sciences of Sichuan University affirmed the achievements of the two sides in scientific research cooperation and talent training in the past. It is hoped that in the future, we can deepen the foundation of cooperation, enrich the content of cooperation, and work with Changrui Biotech to cultivate more biomedical backbone talents who meet the actual needs of enterprises, have innovative vision and practical style.

Director Li of the Bio-city Management Committee congratulated Changrui Biotech on the start of construction and put forward requirements and expectations for the development of the enterprise.

Changrui Biotech will take this as a new starting point, look up at the starry sky, bend down and cultivate, and inject new power sources into accelerating and empowering China's pharmaceutical innovation with actions.

key words: Changrui Biotech held the groundbreaking ceremony and the awarding ceremony of the three bases

relevant